NCT06144788View on ClinicalTrials.gov

Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

April 30, 2025

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

SGLT2 inhibitor

SGLT 1/2 dual inhibitor

Trial Locations (1)

03722

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY